Letrozole
規格
112809-51-5CAS番号
675-034-8EC番号
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrileIUPAC名
C17H11N5化学式
285.3 g/mol分子量
letrozole; 112809-51-5; Femara; Letrozol; CGS 20267; CGS-20267; Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-; DTXSID4023202; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; CGS20267; NSC-759652; 7LKK855W8I; 4-[(4-CYANOPHENYL)(1H-1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE; CHEBI:6413; DTXCID503202; NSC719345; KISQALI FEMARA CO-PACK COMPONENT LETROZOLE; letrozolum; 4-((4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl)benzonitrile; 4-((4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl)benzonitrile; Letrozole Tablets; 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); RefChem:55460; L02BG04; 4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile; 675-034-8; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; C17H11N5; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; CHEMBL1444; NCGC00016973-01; Letoval; CAS-112809-51-5; SMR000466343; Femara (TN); LETRAZOLE; HSDB 7461; SR-01000759382; 4,4'-[(1H-1,2,4-Triazol-1-yl)methylene]dibenzonitrile; Letrozole (JAN/USP/INN); UNII-7LKK855W8I; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; CCRIS 8822; Letrozole?; Letrozole CRS; FEM-345; Femara, Letrozole; Letrozole [USAN:USP:INN:BAN]; Letrozole (Standard); 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; LETROZOLE [INN]; LETROZOLE [JAN]; LETROZOLE [MI]; LETROZOLE [HSDB]; LETROZOLE [USAN]; Prestwick0_001025; Prestwick1_001025; Prestwick2_001025; Prestwick3_001025; Femara (TN) (Novartis); LETROZOLE [MART.]; LETROZOLE [USP-RS]; LETROZOLE [WHO-DD]; SCHEMBL4331; 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; BIDD:PXR0130; BSPBio_001209; MLS000759455; MLS001424038; MLS002584991; MLS006010040; BIDD:GT0015; Letrozole - Bio-X trade mark; SPBio_003070; BPBio1_001331; GTPL5209; orb1308084; LETROZOLE [EP IMPURITY]; LETROZOLE [ORANGE BOOK]; LETROZOLE [EP MONOGRAPH]; Letrozole, >=98% (HPLC); BDBM13061; EX-A965; LETROZOLE [USP MONOGRAPH]; GLXC-05072; HMS1571M11; HMS2051E08; HMS2089L22; HMS2098M11; HMS2233C23; HMS3369E11; HMS3393E08; HMS3651K05; HMS3715M11; HMS5079O19; Pharmakon1600-01502354; IVB71296; MSK10362; Tox21_110719; Tox21_303572; EBC-04408; HY-14248R; MFCD00866241; NSC759652; s1235; AKOS005145822; AB07525; AC-1193; CCG-100849; CS-1776; DB01006; FL24873; KS-1269; NC00099; NSC 759652; NSC-719345; NCGC00016973-02; NCGC00016973-03; NCGC00016973-06; NCGC00016973-19; NCGC00257460-01; BL164620; HY-14248; 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole; 4,2,4-Triazol-1-ylmethylene)dibenzonitrile; AB00514009; L1878; NS00000663; SW197294-4; C08163; D00964; EN300-264820; AB00514009-05; AB00514009-07; AB00514009-08; AB00514009-09; AB00514009_10; AB00514009_11; F036495; Q194974; W-60273; 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile; Q-201291; SR-01000759382-4; SR-01000759382-5; BRD-K88789588-001-03-2; BRD-K88789588-001-14-9; 4,4 -(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; F2173-0288; Z1741968261; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bis[benzonitrile]; Letrozole, European Pharmacopoeia (EP) Reference Standard; Letrozole, United States Pharmacopeia (USP) Reference Standard; 4-[1-(4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE; Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material; CGS 20267; Femara; Lerozole; Letrazole; 4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile; Letrozole Micronized別名
Letrozoleを含む製品
페트라정(레트로졸)레트로보정2.5밀리그램(레트로졸)테바레트로졸정2.5밀리그램파누엘정2.5밀리그램(레트로졸)레나라정(레트로졸)브레트라정(레트로졸)페마라정(레트로졸)FEMARA 2,5 mg COMPRIMIDOS RECUBIERTOS CON PELICULAFEMARA 2,5 mg COMPRIMIDOS RECUBIERTOS CON PELICULAFEMARA 2,5 mg COMPRIMIDOS RECUBIERTOS CON PELICULAFEMARA 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULALETROZOL STADA 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG
1/11ページ
Letrozoleを販売する企業
삼진
삼진제약(주)Republic of Korea(주
(주)보령Republic of Korea신풍
신풍제약(주)Republic of Korea1/9ページ